ClinicalTrials.gg
RecruitingNCT07490301Updated Oct 13, 2026

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 2/3 interventional study of Telisotuzumab adizutecan and Fluorouracil in Metastatic Pancreatic Ductal Adenocarcinoma and PDAC, sponsored by AbbVie. Recruiting at 22 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 13, 2026First site in Portugal3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these ducts. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan when given in combination with fluorouracil, folinic acid, and oxaliplatin (FOLFOX) to treat adult participants with pancreatic ductal cancer.

Telisotuzumab adizutecan is an investigational drug being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study will be divided into two phases, with the first phase (Phase 2) treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX. Participants will then be randomized into 3 groups called treatment arms. Two groups will receive telisotuzumab adizutecan with FOLFOX with different optimized doses. One group will receive standard of care (SOC) - fluorouracil, leucovorin, oxaliplatin, and irinotecan. In the second phase (Phase 3), participants will be randomized into 2 arms to receive either the optimal dose of telisotuzumab adizutecan (from the previous phase) with FOLFOLX, or SOC. Approximately 900 participants with PDAC will be enrolled in this study in approximately 200 sites worldwide.

Phase 2 includes a dose escalation stage and a dose optimization stage. In the dose escalation stage, participants will receive escalating doses of Intravenous (IV) telisotuzumab adizutecan + FOLFOX. In the dose optimization stage, participants will receive 1 of 2 doses of IV telisotuzumab adizutecan with FOLFOX or SOC. At the start of Phase 3, participants will receive the optimal dose of IV telisotuzumab adizutecan with FOLFOX or SOC. The study will run for a duration of approximately 6 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

02

Conditions studied

  • Metastatic Pancreatic Ductal Adenocarcinoma
  • PDAC

Keywords

  • Metastatic Pancreatic Ductal Adenocarcinoma
  • PDAC
  • Telisotuzumab adizutecan
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have unresectable, - or cytologically-confirmed adenocarcinoma of the pancreas
  • Have an (ECOG) performance status (PS) of 0 or 1
  • Must consent to provide archived or recently obtained tumor tissue during Screening
  • Have per (RECIST) v1.1.

Exclusion criteria

Exclusion Criteria:

  • Have prior systemic therapy, surgery, or radiation (except palliative radiation) in the unresectable, locally advanced or setting
  • Prior c-MET targeting therapy
  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic , or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan, including a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
  • Prior bone marrow transplant, solid organ transplant, or previous clinical diagnosis of tuberculosis.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Ph 2: Dose Escalation Telisotuzumab Adizutecan + FOLFOX

    Participants will receive Telisotuzumab Adizutecan + fluorouracil, folinic acid, and oxaliplatin (FOLFOX) until doses for optimization are determined, as part of an approximately 2 year study period.

    Drug: Telisotuzumab adizutecan · Drug: Fluorouracil · Drug: Folinic acid/ Leucovorina · Drug: Oxaliplatin

  • Experimental
    Ph 2: Dose Optimization Telisotuzumab Adizutecan+FOLFOX Dose A

    Participants will receive Telisotuzumab Adizutecan+FOLFOX Dose A as part of the approximately 2 year study duration.

    Drug: Telisotuzumab adizutecan · Drug: Fluorouracil · Drug: Folinic acid/ Leucovorina · Drug: Oxaliplatin

  • Experimental
    Ph 2: Dose Optimization Telisotuzumab Adizutecan+FOLFOX Dose B

    Participants will receive Telisotuzumab Adizutecan+FOLFOX Dose B as part of the approximately 2 year study duration.

    Drug: Telisotuzumab adizutecan · Drug: Fluorouracil · Drug: Folinic acid/ Leucovorina · Drug: Oxaliplatin

  • Active comparator
    Ph 2: Dose Optimization Standard of Care (SOC) mFOLFIRINOX

    Participants will receive SOC (fluorouracil, leucovorin, oxaliplatin, and irinotecan) as part of the approximately 2 year study duration.

    Drug: Fluorouracil · Drug: Folinic acid/ Leucovorina · Drug: Oxaliplatin · Drug: Irinotecan

  • Experimental
    Ph 3: Telisotuzumab Adizutecan RP3D + FOLFOX

    Participants will receive Telisotuzumab Adizutecan recommended Phase 3 dose (RP3D) + FOLFOX as part of an approximately 2 year study period.

    Drug: Telisotuzumab adizutecan · Drug: Fluorouracil · Drug: Folinic acid/ Leucovorina · Drug: Oxaliplatin

  • Active comparator
    Ph 3: SOC mFOLFIRINOX

    Participants will receive SOC (fluorouracil, leucovorin, oxaliplatin, and irinotecan) as part of the approximately 2 year study duration.

    Drug: Fluorouracil · Drug: Folinic acid/ Leucovorina · Drug: Oxaliplatin · Drug: Irinotecan

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    OR is defined as participants achieving a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) assessed by BICR per RECIST v1.1.

    Time frame: through study completion, approximately 6 years

  2. Phase 3: Overall Survival (OS)

    OS is defined as the time from date of randomization to the death from any cause.

    Time frame: through study completion, approximately 6 years

Secondary outcomes

  1. Phase 2 and Phase 3: Progression-Free Survival (PFS) assessed by BICR per RECIST v1.1

    PFS is defined as the time from the date of randomization or date of first dose of study treatment to the first occurrence of radiographic progression assessed by BICR per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: through study completion, approximately 6 years

  2. Phase 2 and Phase 3: Duration Of Response (DoR) assessed by BICR per RECIST v1.1

    DoR is defined as time from the initial response of Complete Response or Partial Response assessed by BICR per RECIST v1.1 to the first occurrence of radiographic progression assessed by BICR per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: through study completion, approximately 6 years

  3. Phase 2 and Phase 3: Clinical Benefit (CB) assessed by BICR per RECIST v1.1

    CB is defined as a participant achieving best overall response of confirmed CR or confirmed PR, or SD (with a minimum duration of 24 weeks) assessed by BICR per RECIST v1.1.

    Time frame: through study completion, approximately 6 years

  4. Phase 2 : Overall Survival

    OS is defined as the time from the date of randomization or date of first dose of study treatment to the event of death from any cause

    Time frame: through study completion, approximately 6 years

  5. Phase 3: Change from baseline and time to deterioration in scale of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - Core 30-item (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Participants rate items on a 4-point scale ranging from 1 (not at all) to 4 (very much).

    Time frame: through study completion, approximately 6 years

  6. Phase 3: Change from baseline and time to deterioration in scale of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - Pancreatic Cancer Module (EORTC QLQ-PAN26)

    The EORTC QLQ-PAN is a PDAC-specific module and consists of 26 questions assessing pancreatic cancer- and treatment-related symptoms and impact, including 7 scales, and 10 single items, All questions employ a one week recall period, and each item is assessed on a Likert scale from 1 (not at all) to 4 (very much).

    Time frame: through study completion, approximately 6 years

  7. Phase 3: Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present).

    Time frame: through study completion, approximately 6 years

  8. Phase 3: Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)

    The FACT GP5 item ("I am bothered by side effects of treatment") is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on patients. This item is rated on a 5- point Likert scale from 0="not at all" to 4="very much."

    Time frame: through study completion, approximately 6 years

  9. Phase 3: Change in Selected items of Patient Global Impression of Severity (PGIS)

    The PGIS scale asks the participant to assess the severity of their PDAC symptoms over the past 7 days and employs a 5-point response scale ranging from "None" to "Very Severe".

    Time frame: through study completion, approximately 6 years

  10. Phase 3: Change in Selected items of Patient Global Impression of Change (PGIC)

    The PGIC scale assesses patients' perceptions of change in their PDAC symptoms since the start of treatment in the study and employs a 7-point response scale ranging from "Much Better" to "Much worse".

    Time frame: through study completion, approximately 6 years

  11. Phase 3: Change from baseline in European Quality of Life 5 Dimensions (EQ-5D-5L)

    The EQ-5D-5L is a generic preference instrument that has been validated in numerous cancer populations. The EQ-5D-5L consists of 2 components: the EQ-5D descriptive system and the EQ VAS. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The EQ VAS records the participant's self-rated health on a vertical VAS where 100 represents "The best health you can imagine" and 0 represents "The worst health you can imagine."

    Time frame: through study completion, approximately 6 years

07

Study locations

22 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jun 2031, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 24, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2031
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in Portugal
Show 3 added (2 Portugal, 1 United States)
  • Smilow Cancer Center At Yale-New Haven /ID# 279780 · New Haven, United States
  • Fundacao Champalimaud /ID# 279881 · Lisbon, Portugal
  • Unidade Local de Saude de Santa Maria /ID# 279884 · Lisbon, Portugal
across 2 updates, Oct 5, 2026 – Oct 13, 2026
Show all 3 updates
  1. Oct 13, 2026
    2 sites added — first site in Portugal
    Show 2 added (2 Portugal)
    • Fundacao Champalimaud /ID# 279881 · Lisbon, Portugal
    • Unidade Local de Saude de Santa Maria /ID# 279884 · Lisbon, Portugal
  2. Oct 5, 2026
    1 site added
    Show site
    • Smilow Cancer Center At Yale-New Haven /ID# 279780 · New Haven, United States
    + 1 other change: verification date
  3. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07490301
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Apr 30, 2026
Primary completion
Jun 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
Oct 13, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telisotuzumab adizutecan

Start the discussion